Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient data

From: Osteoclastic expression of higher-level regulators NFATc1 and BCL6 in medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis

  Number of patients Sex Age (years) (Primary) diagnosis Extraction location Additional information Smoking status
MRONJ (BP) 30 53.3% women (16) Ø 67.8 ± 8.89 33.33% prostate cancer (10), 30% breast cancer (9), 20% multiple myeloma (6),10% osteoporosis (3), 0.33% renal cell carcinoma (1), 0.33% vertebral sclerosis (1) 76.7% lower jaw (23), 23.3% upper jaw (7) 100% nitrogenous. BPs (30):
70% zoledronate (21), 13.3% alendronate (4), 6.6% risedronate (2), 6.6% ibandronate (2), 3.3% pamidronate (1)
13 smoker, 13 non-smoker, 4 unknown
OM 15 53.3% women (8) Ø 43.6 ± 25.20 86.6% chronic osteomyelitis (13), 13.3% acute osteomyelitis (2) 100% lower jaw (15)   6 smoker, 6 non-smoker, 3 unknown
ORN 15 13.3% women (2) Ø 57 ± 7.89 60% SCC oral cavity (9), 13.3% SCC oropharynx (2), 6.6% SCC hypopharynx (1), 6.6% SCC tonsil (1), 6.6% SCC cranial skin (1), 6.6% CUP 100% lower jaw (15) Ø total reference dose in the mandibular region: 68 Gy. (The applicated dose was set individually by the radiotherapists) 11 smoker, 2 non-smoker, 2 unknown
CONTROL 10 40% women (4) Ø 33.8 ± 16.17 50% facial fracture (5), 20% dysgnathia (2), 10% cleft lip and palate (1), 10% wisdom tooth extraction (1), 10% arch ratio anomaly (1) 80% lower jaw (8), 20% upper jaw (2)   2 smoker, 3 non-smoker, 5 unknown
  1. Ø mean, min minimum, max maximum, BP bisphosphonate, MRONJ (BP) medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy, OM osteomyelitis, ORN osteoradionecrosis, SCC squamous cell carcinoma, CUP cancer of unknown primary. The examined patient cohorts were also used in our previous study [12]